← Leaderboards
Patrick J Skelly
Tufts University Boston
$8,349,279
Attributed
$8,576,154
Total exposure
5
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $660K · FY2005–25$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$8,576,154 · 5
By mechanism
R01$6,820,354 · 1
R21$1,343,300 · 3
R56$412,500 · 1
Top collaborators
- Charles Bix Shoemaker2 shared
Most similar at Tufts University Boston
Same institution · by research overlap
- Charles Bix Shoemaker$9,649,281
- Saul R Tzipori$24,857,188
- Greice Krautz-Peterson$165,000
Others in their field
Top investigators on “Rna Interference”
- Norbert Perrimon · Harvard Medical School$46,131,269
- Stuart L Schreiber · Harvard University (Medical School)$43,040,912
- Gary B. Ruvkun · Massachusetts General Hospital$32,268,648
- Scott W Lowe · Sloan-Kettering Inst Can Research$27,556,396
- Judy Lieberman · Boston Children'S Hospital$25,876,315
- Ehud Isacoff · University Of California Berkeley$25,475,182
Research focus
Rna InterferenceSchistosomaParasitesChronicIn VitroEnzymesSchistosomiasisPlatyhelminthsProteinsSurfaceRecombinantsGenesCountryMolecularIn VivoResponsePharmaceutical PreparationsBloodGene ExpressionVaccinesApplications GrantsMonitorReactionHuman Disease
Grant awards (24)
Functional Characterization of the Schistosome Tegument$400,125
R01 · FY2025 · AI · contact PI
Functional Characterization of the Schistosome Tegument$412,500
R01 · FY2024 · AI · contact PI
RNA encoded nanobody-based immunotherapeutics targeting essential, host-interactive schistosome ectoenzymes$206,250
R21 · FY2024 · AI · contact PI
RNA encoded nanobody-based immunotherapeutics targeting essential, host-interactive schistosome ectoenzymes$247,500
R21 · FY2023 · AI · contact PI
Functional Characterization of the Schistosome Tegument$412,500
R56 · FY2021 · AI · contact PI
Functional Characterization of the Schistosome Tegument$412,500
R01 · FY2019 · AI · contact PI
Tegumental acetylcholinesterase as a therapeutic target for schistosomiasis$206,250
R21 · FY2019 · AI · contact PI
Functional Characterization of the Schistosome Tegument$412,500
R01 · FY2018 · AI · contact PI
Tegumental acetylcholinesterase as a therapeutic target for schistosomiasis$247,500
R21 · FY2018 · AI · contact PI
Functional Characterization of the Schistosome Tegument$412,500
R01 · FY2017 · AI · contact PI
Functional Characterization of the Schistosome Tegument$412,500
R01 · FY2016 · AI · contact PI
Functional Characterization of the Schistosome Tegument$412,500
R01 · FY2015 · AI · contact PI
Inhibiting tegumental carbonic anhydrase as a novel treatment for schistosomiasis$230,400
R21 · FY2015 · AI · contact PI
Functional Characterization of the Schistosome Tegument$408,375
R01 · FY2014 · AI · contact PI
Inhibiting tegumental carbonic anhydrase as a novel treatment for schistosomiasis$205,400
R21 · FY2014 · AI · contact PI
Functional Characterization of the Schistosome Tegument$383,873
R01 · FY2013 · AI · contact PI
Functional Characterization of the Schistosome Tegument$408,375
R01 · FY2012 · AI · contact PI
Functional Characterization of the Schistosome Tegument$408,375
R01 · FY2011 · AI · contact PI
Functional Characterization of the Schistosome Tegument$412,500
R01 · FY2010 · AI · contact PI
Gene silencing in schistosomes using RNAi$368,577
R01 · FY2008 · AI · contact PI
Gene silencing in schistosomes using RNAi$375,716
R01 · FY2007 · AI · contact PI
Gene silencing in schistosomes using RNAi$386,938
R01 · FY2006 · AI · contact PI
Gene silencing in schistosomes using RNAi$396,250
R01 · FY2005 · AI
Gene silencing in schistosomes using RNAi$396,250
R01 · FY2004 · AI